-
Product Insights
Ocular Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Melanoma - Drugs In Development, 2023’, provides an overview of the Ocular Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Uveal Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveal Melanoma - Drugs In Development, 2023’, provides an overview of the Uveal Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Infusion Systems Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Infusion Systems Pipeline Market Report Overview Infusion systems are used to administer medication to a patients in critical care, emergency care, home care, and trauma centres. The infusion systems pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ABP-671 in Hyperuricemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ABP-671 in Hyperuricemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ABP-671 in Hyperuricemia Drug Details: ABP-671 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SKL-27969 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SKL-27969 in High-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SKL-27969 in High-Grade GliomaDrug Details:SKL-27969 is under development for the treatment of advanced...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KNK-003 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KNK-003 in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KNK-003 in Chronic Myelocytic Leukemia (CML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SD-101 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SD-101 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SD-101 in Pancreatic Ductal Adenocarcinoma Drug Details: SD-101 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAR-442257 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SAR-442257 in Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy Drug Details: SAR-442257 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SD-101 in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SD-101 in Hepatocellular Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SD-101 in Hepatocellular Carcinoma Drug Details: SD-101 is under development for the...